These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 29941152)
41. Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D. Zhu D; Trinh P; Li J; Grant GA; Yang F J Biomed Mater Res A; 2021 Jun; 109(6):1027-1035. PubMed ID: 32862485 [TBL] [Abstract][Full Text] [Related]
42. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. Wang S; Chen C; Li J; Xu X; Chen W; Li F J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273 [TBL] [Abstract][Full Text] [Related]
43. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species. Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068 [TBL] [Abstract][Full Text] [Related]
44. Investigating Trans-differentiation of Glioblastoma Cells in an Hatlen RR; Rajagopalan P ACS Biomater Sci Eng; 2023 Jun; 9(6):3445-3461. PubMed ID: 37129167 [TBL] [Abstract][Full Text] [Related]
45. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610 [TBL] [Abstract][Full Text] [Related]
46. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214 [TBL] [Abstract][Full Text] [Related]
47. Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma. Wang M; Xia D; Xu D; Yin Y; Xu F; Zhang B; Li K; Yang Z; Zou J Cancer Lett; 2024 Feb; 582():216593. PubMed ID: 38092144 [TBL] [Abstract][Full Text] [Related]
48. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? He Y; Kaina B Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722 [TBL] [Abstract][Full Text] [Related]
49. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757 [TBL] [Abstract][Full Text] [Related]
50. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance. Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184 [TBL] [Abstract][Full Text] [Related]
51. The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma. Hu K; Li J; Wu G; Zhou L; Wang X; Yan Y; Xu Z Aging (Albany NY); 2021 Feb; 13(5):6662-6680. PubMed ID: 33621203 [TBL] [Abstract][Full Text] [Related]
52. Transcriptional control of O Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969 [TBL] [Abstract][Full Text] [Related]
53. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025 [TBL] [Abstract][Full Text] [Related]
54. Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108161 [TBL] [Abstract][Full Text] [Related]
55. Curcumin combining temozolomide formed localized nanogel for inhibition of postsurgical chemoresistant glioblastoma. Liang Q; Zhuo Y; Wu X; Zheng S; Zhuang J; Wang K; Chen S Nanomedicine (Lond); 2023 May; 18(12):907-921. PubMed ID: 37466022 [TBL] [Abstract][Full Text] [Related]
56. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679 [TBL] [Abstract][Full Text] [Related]
57. Gelatin Methacryloyl Hydrogels in the Absence of a Crosslinker as 3D Glioblastoma Multiforme (GBM)-Mimetic Microenvironment. Erkoc P; Seker F; Bagci-Onder T; Kizilel S Macromol Biosci; 2018 Mar; 18(3):. PubMed ID: 29333657 [TBL] [Abstract][Full Text] [Related]
58. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma. Chen C; Han G; Li Y; Yue Z; Wang L; Liu J J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501 [TBL] [Abstract][Full Text] [Related]
59. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
60. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]